Q2 EPS Forecast for BriaCell Therapeutics Raised by Analyst

BriaCell Therapeutics Corp. (TSE:BCT - Free Report) - Equities research analysts at HC Wainwright lifted their Q2 2025 EPS estimates for shares of BriaCell Therapeutics in a research note issued on Monday, February 3rd. HC Wainwright analyst E. Bodnar now anticipates that the company will earn ($2.83) per share for the quarter, up from their previous forecast of ($5.70). HC Wainwright also issued estimates for BriaCell Therapeutics' Q3 2025 earnings at ($1.63) EPS, Q4 2025 earnings at ($1.66) EPS, FY2025 earnings at ($3.57) EPS, FY2026 earnings at ($2.14) EPS, FY2027 earnings at ($1.59) EPS, FY2028 earnings at ($1.01) EPS and FY2029 earnings at ($0.35) EPS.

BriaCell Therapeutics Stock Up 8.5 %

TSE:BCT traded up C$0.51 during trading hours on Wednesday, reaching C$6.48. 21,172 shares of the company's stock were exchanged, compared to its average volume of 12,665. The firm has a market capitalization of C$232.24 million, a price-to-earnings ratio of -12.96 and a beta of 1.83. The company has a 50-day moving average of C$1.66 and a 200 day moving average of C$1.24. BriaCell Therapeutics has a 1-year low of C$5.68 and a 1-year high of C$86.85.

BriaCell Therapeutics Company Profile

BriaCell Therapeutics Corp. operates as a Phase 3 biotechnology company transforming cancer care with its novel cellular immunotherapies. It is conducting a pivotal Phase 3 clinical trial in advanced breast cancer with its Bria-IMT in combination with an immune check point inhibitor. It is also developing personalized off-the-shelf treatments for breast cancer, prostate cancer, and other cancers.